Marie Amougou Atsama1, Paul Jean Adrien Atangana2, Dominique Noah Noah3, Paul Fewou Moundipa4, Pascal Pineau5, Richard Njouom6. 1. Centre Pasteur of Cameroon, Yaounde, Cameroon; Laboratory of Pharmacology and Toxicology of University of Yaounde I, Yaounde, Cameroon. Electronic address: marieamougou164@yahoo.com. 2. Centre Pasteur of Cameroon, Yaounde, Cameroon. Electronic address: atangana@pasteur-yaounde.org. 3. Central Hospital of Yaounde, Yaounde, Cameroon. Electronic address: noahnoahd@yahoo.fr. 4. Laboratory of Pharmacology and Toxicology of University of Yaounde I, Yaounde, Cameroon. Electronic address: pmoundipa@hotmail.com. 5. Unité « Organisation nucléaire et Oncogenèse », INSERM U993, Institut Pasteur, Paris, France. Electronic address: pascal.pineau@pasteur.fr. 6. Centre Pasteur of Cameroon, Yaounde, Cameroon. Electronic address: njouom@pasteur-yaounde.org.
Abstract
OBJECTIVES: To determine the seroprevalence of hepatitis E virus (HEV) infection in patients with chronic hepatitis and/or hepatocellular carcinoma (HCC) and to assess its potential consequences for disease progression. METHODS: We conducted a prospective case-control study on patients with HCC hepatitis B or C related and non-HCC patients including patients with CLD and patients without clinical evidence of liver disease. Anti-HEV IgG and IgM were tested by ELISA using commercially available kits. Liver damage was assessed by alanine aminotransferase, aspartate aminotransferase, platelets and prothrombin measurements. RESULTS: We observed a significant anti-HEV IgG carriage in HCC patients compared to non-HCC subjects with CLD (41.8% vs 12.6%; P=9.1 E-6; OR=4.8, 95%CI: 2.3-10.6). HCC patients with HEV infection display more profound alterations of circulating liver enzymes, platelets count and prothrombin time than HCC patients without sero-reactivity to HEV. CONCLUSION: Overall, this study indicates a high prevalence of HEV infection in Cameroonian patients with CLD and HCC. These data suggest either that patients with liver tumors are more susceptible to hepeviral infection or that, in a tropical context, HEV might promote the progression of liver diseases towards tumor.
OBJECTIVES: To determine the seroprevalence of hepatitis E virus (HEV) infection in patients with chronic hepatitis and/or hepatocellular carcinoma (HCC) and to assess its potential consequences for disease progression. METHODS: We conducted a prospective case-control study on patients with HCC hepatitis B or C related and non-HCC patients including patients with CLD and patients without clinical evidence of liver disease. Anti-HEV IgG and IgM were tested by ELISA using commercially available kits. Liver damage was assessed by alanine aminotransferase, aspartate aminotransferase, platelets and prothrombin measurements. RESULTS: We observed a significant anti-HEV IgG carriage in HCC patients compared to non-HCC subjects with CLD (41.8% vs 12.6%; P=9.1 E-6; OR=4.8, 95%CI: 2.3-10.6). HCC patients with HEV infection display more profound alterations of circulating liver enzymes, platelets count and prothrombin time than HCC patients without sero-reactivity to HEV. CONCLUSION: Overall, this study indicates a high prevalence of HEV infection in Cameroonian patients with CLD and HCC. These data suggest either that patients with liver tumors are more susceptible to hepeviral infection or that, in a tropical context, HEV might promote the progression of liver diseases towards tumor.
Authors: Mohammed Elhendawy; Lobna Abo-Ali; Sherief Abd-Elsalam; Maha M Hagras; Ibrahim Kabbash; Loai Mansour; Sherief Atia; Gamal Esmat; Abdel-Raouf Abo-ElAzm; Ferial El-Kalla; Abdelrahman Kobtan Journal: Environ Sci Pollut Res Int Date: 2020-06-12 Impact factor: 4.223